NCT01756495 - A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2013

Primary Completion Date

April 23, 2013

Study Completion Date

April 23, 2013

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Losmapimod

Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods

DRUG

Moxifloxacin

17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods

DRUG

Losmapimod matched Placebo

Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods

DRUG

Moxifloxacin Placebo

16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods

Trial Locations (1)

21225

GSK Investigational Site, Baltimore